Mekinist

Summary

Name(s) Target Manufacturer Status
Mekinist, trametinib MAP2K1, MAP2K2 GlaxoSmithKline FDA approved for: Melanoma, BRAF V600E Mutated, Melanoma, BRAF V600K Mutated

Clinical Trials

Trial Drug Status Phase
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. [NCT01682083] Mekinist, Tafinlar Recruiting Phase 3
Trametinib With GSK2141795 in BRAF Wild-type Melanoma [NCT01941927] GSK2141795, Mekinist Recruiting Phase 2
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [NCT01726738] Mekinist, Tafinlar Recruiting Phase 2
GSK2118436 and GSK1120212 [NCT01619774] Tafinlar, Mekinist Recruiting Phase 2
A Single Cohort Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Exploratory Translational Research, and Safety Endpoints of Preoperative Treatment of GSK2118436 in Subjects With BRAF V600E or V600K Mutation-positive Metastatic Melanoma to th... [NCT01978236] Mekinist, Tafinlar Not yet recruiting Phase 2
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery [NCT01701037] Mekinist, Tafinlar Recruiting Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma [NCT01979523] GSK2141795, Mekinist Recruiting Phase 2
NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors [NCT01827384] Afinitor, Carboplatin, MK-1775, Mekinist, Temodar, veliparib Recruiting Phase 2
GSK1120212 Rollover Study [NCT01376310] Abraxane, Afinitor, Alimta, Carboplatin, Gemzar, Mekinist, Tarceva, Taxotere Recruiting Phase 2
Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery [NCT01970956] ABT-263, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery [NCT01989585] ABT-263, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [NCT01725100] Mekinist Recruiting Phase 1
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma [NCT01767454] Mekinist, Tafinlar, Yervoy Recruiting Phase 1
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 [NCT01658553] Mekinist Recruiting Phase 1
Trametinib in Treating Patients With Advanced Cancer and Hepatic Dysfunction [NCT02007382] Mekinist Recruiting Phase 1
Trametinib in Treating Patients With Advanced Cancer and Hepatic Dysfunction [NCT02070549] Mekinist Recruiting Phase 1
Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery [NCT01940809] Mekinist, Tafinlar, Yervoy Recruiting Phase 1
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma [NCT01438554] Mekinist, Votrient Recruiting Phase 1
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors [NCT01231594] Mekinist, Tafinlar Recruiting Phase 1
Safety, PK of AKT and MEK Combination [NCT01138085] GSK2141795, Mekinist Recruiting Phase 1
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases [NCT02015117] Mekinist Recruiting Phase 1
A Study of LY2875358 in Participants With Advanced Cancer [NCT01287546] LY2875358, Mekinist, Tarceva Recruiting Phase 1
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors [NCT02065063] Mekinist, PD-0332991 Not yet recruiting Phase 1
Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery [NCT02097225] AT13387, Mekinist, Tafinlar Not yet recruiting Phase 1

Suggested Reading / Relevant Literature

#